Cargando…

Convalescent fecal microbiota transplantation as a possible treatment for COVID-19

Detalles Bibliográficos
Autores principales:	Apartsin, Konstantin, Smirnova, Valentina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Masson SAS. 2020
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7473027/ https://www.ncbi.nlm.nih.gov/pubmed/32917563 http://dx.doi.org/10.1016/j.clinre.2020.08.003

Ejemplares similares

Convalescent plasma: A possible treatment of COVID-19 in India
por: Teixeira da Silva, Jaime A.
Publicado: (2020)

Fecal Microbiota Transplantation and the Brain Microbiota in Neurological Diseases
por: Ruggiero, Marco
Publicado: (2016)

‘Treatment of COVID-19 with convalescent plasma’ – Author’s reply
por: Wooding, Denise J., et al.
Publicado: (2021)

High-Dose Convalescent Plasma for Treatment of Severe COVID-19
por: Focosi, Daniele, et al.
Publicado: (2022)

Convalescent plasma for COVID-19 considerations
por: Adiwinata Pawitan, Jeanne
Publicado: (2021)

Fecal microbiota transplantation as potential first-line treatment for patients with Clostridioides difficile infection and prior appendectomy
por: Zhao, Jing-Wen, et al.
Publicado: (2023)

Fecal microbiota transplantation for steroid-refractory gastrointestinal graft-versus-host disease
por: Kim, Hyun Min, et al.
Publicado: (2023)

A Survey Using the Social Networks Revealed Poor Knowledge on Fecal Microbiota Transplantation
por: Orduña, Patricia, et al.
Publicado: (2015)

High-Dose Convalescent Plasma for Treatment of Severe COVID-19 (response)
por: De Santis, Gil C., et al.
Publicado: (2022)

Convalescent plasma in the management of COVID-19 pneumonia
por: Elbadawi, Ayman, et al.
Publicado: (2021)

How Safe Is COVID-19 Convalescent Plasma?
por: Franchini, Massimo, et al.
Publicado: (2021)

COVID-19 convalescent plasma therapy and immunodeficiency
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2021)

Use of convalescent plasma in COVID-19 patients in China
por: Zhu, M., et al.
Publicado: (2020)

Convalescent plasma (CP) therapy in patients with COVID-19
por: Cakir, Banu
Publicado: (2021)

In Reply—How Safe Is COVID-19 Convalescent Plasma?
por: Joyner, Michael J., et al.
Publicado: (2021)

Fecal microbiota transplantation against irritable bowel syndrome? Rigorous randomized clinical trials are required
por: Abadi, Amin Talebi Bezmin
Publicado: (2017)

Is it reasonable to perform Fecal Microbiota Transplantation for recurrent Clostridium difficile Infection in patients with liver cirrhosis?
por: Olmedo, Maria, et al.
Publicado: (2019)

Can hyperimmune anti-CMV globulin substitute for convalescent plasma for treatment of COVID-19?
por: Basic-Jukic, Nikolina
Publicado: (2020)

Fecal Microbiota Transplantation Inhibits Multidrug-Resistant Gut Pathogens: Preliminary Report Performed in an Immunocompromised Host
por: Biliński, Jarosław, et al.
Publicado: (2016)

Fecal Microbiota Transplantation in NAFLD Treatment
por: Abenavoli, Ludovico, et al.
Publicado: (2022)

Fecal microbiota transplantation is feasible even in critically ill patients with toxic megacolon due to Clostridium difficile infection
por: Zybura, Joanna, et al.
Publicado: (2020)

Decolonization of multi-drug resistant bacteria by fecal microbiota transplantation in five pediatric patients before allogeneic hematopoietic stem cell transplantation: gut microbiota profiling, infectious and clinical outcomes
por: Merli, Pietro, et al.
Publicado: (2020)

Limitations of Safety Update on Convalescent Plasma Transfusion in COVID-19 Patients
por: Farag, Youssef M.K.
Publicado: (2020)

Convalescent plasma to treat COVID-19: Its challenges in Iraq's situation
por: Hashim, H.T.
Publicado: (2020)

Iran’s Experience in Establishing Convalescent Care Facilities for Patients With COVID-19
por: Maher, Ali, et al.
Publicado: (2020)

Challenges in the production of COVID-19 convalescent plasma- analysis of donor recruitment
por: Sekiya, Eliseo Joji, et al.
Publicado: (2021)

Clot-in-transit cardiopulmonary thrombosis during convalescent phase of COVID-19
por: Karippacheril, John George, et al.
Publicado: (2022)

COVID-19 vaccination: The impact on the selection criteria of the convalescent plasma donors
por: Bansal, N., et al.
Publicado: (2021)

The emergency use authorization for COVID‐19 convalescent plasma reduced mortality
por: Paneth, Nigel, et al.
Publicado: (2023)

Fecal‐oral transmission of COVID‐19
por: Joob, Beuy, et al.
Publicado: (2020)

Implementation of veno-venous extracorporeal membrane oxygenation in a COVID-19 convalescent
por: Gawda, Ryszard, et al.
Publicado: (2020)

Fecal β-glucuronidase activity differs between hematopoietic cell and kidney transplantation and a possible mechanism for disparate dose requirements
por: Khan, Mohammad Haneef, et al.
Publicado: (2022)

In Reply — Limitations of Safety Update on Convalescent Plasma Transfusion in COVID-19 Patients
por: Joyner, Michael. J., et al.
Publicado: (2020)

Early and persistent viral clearance in COVID-19 patients treated with convalescent plasma
por: Franchini, Massimo, et al.
Publicado: (2021)

Neutralizing Autoantibodies to Type I Interferons in COVID-19 Convalescent Donor Plasma
por: Vazquez, Sara E., et al.
Publicado: (2021)

Covid-19 convalescent plasma and SARS-CoV-2 viral variants
por: Joob, B., et al.
Publicado: (2021)

Antimicrobial stewardship programs and convalescent plasma for COVID-19: A new paradigm for preauthorization?
por: Stevens, Michael P., et al.
Publicado: (2020)

Canine Fecal Microbiota Transplantation: Current Application and Possible Mechanisms
por: Tuniyazi, Maimaiti, et al.
Publicado: (2022)

Severe COVID-19 in Patients with B Cell Alymphocytosis and Response to Convalescent Plasma Therapy
por: London, Jonathan, et al.
Publicado: (2020)

COVID-19 convalescent plasma therapy for immunodeficient patients–weighing up risks and benefits
por: Vuk, T., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mthem82fqp4jbqbaetpvi00rl8